CA2669727C - Alcohol free formulation of argatroban - Google Patents

Alcohol free formulation of argatroban Download PDF

Info

Publication number
CA2669727C
CA2669727C CA2669727A CA2669727A CA2669727C CA 2669727 C CA2669727 C CA 2669727C CA 2669727 A CA2669727 A CA 2669727A CA 2669727 A CA2669727 A CA 2669727A CA 2669727 C CA2669727 C CA 2669727C
Authority
CA
Canada
Prior art keywords
salt
argatroban
formulation
acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2669727A
Other languages
English (en)
French (fr)
Other versions
CA2669727A1 (en
Inventor
Nageswara R. Palepu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eagle Pharmaceuticals Inc
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39230808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2669727(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of CA2669727A1 publication Critical patent/CA2669727A1/en
Application granted granted Critical
Publication of CA2669727C publication Critical patent/CA2669727C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2669727A 2006-09-27 2007-09-26 Alcohol free formulation of argatroban Active CA2669727C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84755606P 2006-09-27 2006-09-27
US60/847,556 2006-09-27
US85072506P 2006-10-11 2006-10-11
US60/850,725 2006-10-11
PCT/US2007/020725 WO2008039473A2 (en) 2006-09-27 2007-09-26 Alcohol free formulation of argatroban

Publications (2)

Publication Number Publication Date
CA2669727A1 CA2669727A1 (en) 2008-04-03
CA2669727C true CA2669727C (en) 2014-10-28

Family

ID=39230808

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2669727A Active CA2669727C (en) 2006-09-27 2007-09-26 Alcohol free formulation of argatroban

Country Status (5)

Country Link
US (1) US7589106B2 (enExample)
EP (1) EP2083823A4 (enExample)
JP (1) JP5624766B2 (enExample)
CA (1) CA2669727C (enExample)
WO (1) WO2008039473A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915290B2 (en) * 2008-02-29 2011-03-29 Baxter International Inc. Argatroban formulations and methods for making and using same
HUE045889T2 (hu) 2010-10-21 2020-01-28 Rtu Pharmaceuticals Llc Használatkész ketorolak készítmények
EP2884963B1 (en) * 2012-08-15 2017-12-27 Yung Shin Pharm. Ind. Co. Ltd. Stable pharmaceutical formulation of cabazitaxel
US9636376B2 (en) 2012-09-11 2017-05-02 Innopharma, Inc. Stable compositions of peptide epoxy ketones

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214052A (en) 1987-07-28 1993-05-25 Mitsubishi Kasei Corporation Method for dissolving arginineamides and pharmaceutical compositions containing them
US5506241A (en) 1992-03-18 1996-04-09 Mitsubishi Chemical Corporation Argatroban preparations for ophthalmic use
JPH06219948A (ja) 1993-01-25 1994-08-09 Mitsubishi Kasei Corp 抗トロンビン剤及びその製造方法
JPH06219949A (ja) * 1993-01-25 1994-08-09 Mitsubishi Kasei Corp 抗トロンビン剤及びその製造方法
JPH07228532A (ja) * 1993-04-22 1995-08-29 Senju Pharmaceut Co Ltd 水性液剤、その有効成分の溶解性向上方法および安定化方法
TW256831B (enExample) 1993-04-22 1995-09-11 Senju Pharma Co
FR2715566B1 (fr) 1994-02-03 1996-03-08 Synthelabo Solutions aqueuses concentrées d'argatroban.
CA2345641A1 (en) 1998-09-28 2000-04-06 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
WO2004026252A2 (en) 2002-09-23 2004-04-01 The Regents Of The University Of Michigan Glioma treatments
CN101257890B (zh) * 2005-09-01 2012-10-31 巴克斯特国际公司 含有酸作为增溶剂的阿加曲班制剂

Also Published As

Publication number Publication date
US20080076798A1 (en) 2008-03-27
JP5624766B2 (ja) 2014-11-12
WO2008039473A2 (en) 2008-04-03
US7589106B2 (en) 2009-09-15
CA2669727A1 (en) 2008-04-03
EP2083823A4 (en) 2010-01-13
WO2008039473A3 (en) 2008-06-12
EP2083823A2 (en) 2009-08-05
JP2010504971A (ja) 2010-02-18

Similar Documents

Publication Publication Date Title
JP2005002123A5 (enExample)
JP2018109005A (ja) ベンダムスチン製剤
JP2008543789A (ja) ドセタキセルの液体薬学的処方物
AU2015256331B2 (en) Formulations of Cyclophosphamide liquid concentrate
US20190060393A1 (en) Stable compositions of peptide expoxy ketones
JP2012158521A (ja) 外用剤
CA2669727A1 (en) Alcohol free formulation of argatroban
EA033988B1 (ru) Инъецируемые фармацевтические композиции лефамулина
JP6347784B2 (ja) 神経筋遮断薬の安定化水性組成物
US20130023559A1 (en) Alcohol free formulation of argatroban
WO2008045410A2 (en) Alcohol free formulation of argatroban
CA2625862A1 (en) Liquid pharmaceutical compositions of nimodipine
TWI327910B (enExample)
JP2010504971A5 (enExample)
CN101516370A (zh) 阿加曲班的无醇制剂
US7687516B2 (en) Alcohol free formulation of argatroban
JPH0576929B2 (enExample)
US20190070136A1 (en) Parenteral compositions of carmustine
JPH11228404A (ja) 安定な水性点眼剤
HK1131895A (en) Alcohol free formulation of argatroban
AU2008250717A1 (en) Aqueous pharmaceutical preparation
US20250268875A1 (en) Stabilized pharmaceutical composition of 1,4-dihydropyridines with hydrogen atom transfer (hat) antioxidants
US20090062295A1 (en) Pharmaceutical Products
TW202228718A (zh) 福沙吡坦注射用水溶液劑、福沙吡坦注射用水溶液劑中福沙吡坦類似物質的生成抑制劑以及生成抑制方法、二乙三胺五乙酸的用途
WO2023126531A1 (en) Lenalidomide oral solution

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240920

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240920

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240920

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250919

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250919